CD274 and non-small cell lung carcinoma: Targeted therapies and ICI, specifically programmed death-1/programmed death-ligand1 (PD-1/PD-L1) inhibitors, have become available over the last decade with the first ICI approved in 2015 for previously treated unresectable advanced/metastatic NSCLC (10).